Switch to:
Also traded in: Austria, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
CELG's Cash-to-Debt is ranked lower than
95% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. CELG: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
CELG' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 2.2 Max: No Debt
Current: No Debt
0.03
No Debt
Equity-to-Asset 0.17
CELG's Equity-to-Asset is ranked lower than
91% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CELG: 0.17 )
Ranked among companies with meaningful Equity-to-Asset only.
CELG' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.68  Med: 0.73 Max: 0.98
Current: 0.17
-0.68
0.98
Debt-to-Equity 4.17
CELG's Debt-to-Equity is ranked lower than
99% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. CELG: 4.17 )
Ranked among companies with meaningful Debt-to-Equity only.
CELG' s Debt-to-Equity Range Over the Past 10 Years
Min: -4.28  Med: 0.54 Max: 6.2
Current: 4.17
-4.28
6.2
Debt-to-EBITDA 3.28
CELG's Debt-to-EBITDA is ranked lower than
72% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. CELG: 3.28 )
Ranked among companies with meaningful Debt-to-EBITDA only.
CELG' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.97  Med: 2.31 Max: 5.18
Current: 3.28
0.97
5.18
Interest Coverage 7.16
CELG's Interest Coverage is ranked lower than
92% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CELG: 7.16 )
Ranked among companies with meaningful Interest Coverage only.
CELG' s Interest Coverage Range Over the Past 10 Years
Min: 6.41  Med: 25.97 Max: 428.04
Current: 7.16
6.41
428.04
Piotroski F-Score: 4
Altman Z-Score: 3.08
Beneish M-Score: -2.74
WACC vs ROIC
11.82%
30.19%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 34.70
CELG's Operating Margin % is ranked higher than
87% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. CELG: 34.70 )
Ranked among companies with meaningful Operating Margin % only.
CELG' s Operating Margin % Range Over the Past 10 Years
Min: 12.23  Med: 28.57 Max: 34.78
Current: 34.7
12.23
34.78
Net Margin % 26.48
CELG's Net Margin % is ranked higher than
90% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. CELG: 26.48 )
Ranked among companies with meaningful Net Margin % only.
CELG' s Net Margin % Range Over the Past 10 Years
Min: -68.02  Med: 23.45 Max: 28.88
Current: 26.48
-68.02
28.88
ROE % 76.21
CELG's ROE % is ranked higher than
97% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. CELG: 76.21 )
Ranked among companies with meaningful ROE % only.
CELG' s ROE % Range Over the Past 10 Years
Min: -48.42  Med: 25.73 Max: 76.21
Current: 76.21
-48.42
76.21
ROA % 12.05
CELG's ROA % is ranked higher than
90% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. CELG: 12.05 )
Ranked among companies with meaningful ROA % only.
CELG' s ROA % Range Over the Past 10 Years
Min: -38.07  Med: 11.43 Max: 15.8
Current: 12.05
-38.07
15.8
ROC (Joel Greenblatt) % 396.60
CELG's ROC (Joel Greenblatt) % is ranked higher than
97% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. CELG: 396.60 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CELG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -421.4  Med: 179.18 Max: 408.45
Current: 396.6
-421.4
408.45
3-Year Revenue Growth Rate 20.60
CELG's 3-Year Revenue Growth Rate is ranked higher than
77% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. CELG: 20.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CELG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -37  Med: 32.2 Max: 241.3
Current: 20.6
-37
241.3
3-Year EBITDA Growth Rate 24.10
CELG's 3-Year EBITDA Growth Rate is ranked higher than
76% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. CELG: 24.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CELG' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 13.1 Max: 173.3
Current: 24.1
0
173.3
3-Year EPS without NRI Growth Rate 15.10
CELG's 3-Year EPS without NRI Growth Rate is ranked higher than
63% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. CELG: 15.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CELG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 9.65 Max: 109.7
Current: 15.1
0
109.7
GuruFocus has detected 3 Warning Signs with Celgene Corp CELG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CELG's 30-Y Financials

Financials (Next Earnings Date: 2019-05-03)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2018

CELG Guru Trades in Q1 2018

Paul Tudor Jones 68,005 sh (New)
Mairs and Power 3,030 sh (New)
Scott Black 20,260 sh (New)
Ken Fisher 309,343 sh (+33.85%)
Ronald Muhlenkamp 72,493 sh (+3.41%)
Joel Greenblatt 388,970 sh (+93.58%)
Richard Pzena 4,825 sh (+103.50%)
Spiros Segalas 3,884,214 sh (+21.11%)
Jim Simons 2,570,838 sh (+222.89%)
Pioneer Investments 851,304 sh (+4.50%)
Ray Dalio 452,364 sh (+55.57%)
Frank Sands 65,744 sh (+49.69%)
Steven Cohen 100,000 sh (unchged)
Tom Russo Sold Out
First Pacific Advisors Sold Out
Signature Select Canadian Fund Sold Out
Murray Stahl 7,000 sh (-11.39%)
Steven Cohen 96,800 sh (-51.60%)
Mario Gabelli 3,100 sh (-8.82%)
David Rolfe 924,542 sh (-3.93%)
Eaton Vance Worldwide Health Sciences Fund 274,651 sh (-28.95%)
» More
Q2 2018

CELG Guru Trades in Q2 2018

Ken Fisher 322,086 sh (+4.12%)
Joel Greenblatt 565,173 sh (+45.30%)
Murray Stahl 7,030 sh (+0.43%)
Paul Tudor Jones 172,031 sh (+152.97%)
Pioneer Investments 874,432 sh (+2.72%)
Ray Dalio 546,369 sh (+20.78%)
Jim Simons 4,129,438 sh (+60.63%)
Ronald Muhlenkamp 72,493 sh (unchged)
Steven Cohen Sold Out
Frank Sands Sold Out
Scott Black Sold Out
Richard Pzena 4,518 sh (-6.36%)
Spiros Segalas 2,740,138 sh (-29.45%)
Mairs and Power 2,980 sh (-1.65%)
Mario Gabelli 3,000 sh (-3.23%)
David Rolfe 864,236 sh (-6.52%)
Eaton Vance Worldwide Health Sciences Fund 225,793 sh (-17.79%)
» More
Q3 2018

CELG Guru Trades in Q3 2018

Steven Cohen 670,181 sh (New)
Ken Fisher 323,435 sh (+0.42%)
Pioneer Investments 1,025,733 sh (+17.30%)
Eaton Vance Worldwide Health Sciences Fund 225,793 sh (unchged)
Richard Pzena 4,518 sh (unchged)
Murray Stahl 7,030 sh (unchged)
Mario Gabelli Sold Out
Spiros Segalas 2,596,990 sh (-5.22%)
Ronald Muhlenkamp 72,116 sh (-0.52%)
Ray Dalio 426,026 sh (-22.03%)
Jim Simons 1,553,438 sh (-62.38%)
Mairs and Power 2,940 sh (-1.34%)
David Rolfe 757,374 sh (-12.36%)
Joel Greenblatt 327,705 sh (-42.02%)
Paul Tudor Jones 98,763 sh (-42.59%)
» More
Q4 2018

CELG Guru Trades in Q4 2018

Ken Fisher 341,865 sh (+5.70%)
Ray Dalio 878,145 sh (+106.12%)
Steven Cohen 1,651,513 sh (+146.43%)
Joel Greenblatt 617,900 sh (+88.55%)
Eaton Vance Worldwide Health Sciences Fund 225,793 sh (unchged)
Richard Pzena 4,518 sh (unchged)
Steven Cohen 100,000 sh (unchged)
Mairs and Power Sold Out
Spiros Segalas 2,296,477 sh (-11.57%)
Jim Simons 1,279,838 sh (-17.61%)
Murray Stahl 7,019 sh (-0.16%)
Paul Tudor Jones 14,054 sh (-85.77%)
David Rolfe 654,632 sh (-13.57%)
Pioneer Investments 865,456 sh (-15.63%)
» More
» Details

Insider Trades

Latest Guru Trades with CELG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:ASX:CSL, NAS:BIIB, LSE:SHP, NAS:GILD, NAS:VRTX, NAS:REGN, XKRX:068270, XKRX:207940, NAS:ALXN, OCSE:NOVO B, NAS:AMGN, HKSE:01177, XMCE:GRF.P, NAS:BMRN, XBRU:UCB, NAS:NKTR, OCSE:NZYM B, NAS:INCY, OCSE:GEN, NAS:BIVV » details
Traded in other countries:CELG.Austria, CLGN34.Brazil, CG3.Germany, CELG.Mexico, CELG.Switzerland, 0QYA.UK,
Headquarter Location:USA
Celgene Corp is a biotech company that discovers, develops, and commercializes therapies designed to treat cancer and immune-inflammatory related diseases. Its registered brands are Abraxane, Istodax, Otezla, Pomalyst, Revlimid, Thalomid, Vidaza.

Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Pending acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.

Guru Investment Theses on Celgene Corp

David Rolfe Comments on Celgene - Jan 15, 2019

Celgene (NASDAQ:CELG) challenged us for the quarter, and quite frankly, the full year, as management failed to deliver on their promising pipeline of drugs. In review of the year, Celgene came out swinging with their $9 billion acquisition of Juno in January 2018, which brought into the Celgene portfolio of drugs JCAR017 (now liso-cell, for B-cell non-Hodgkin lymphoma) and JCARH125 (BCMA for multiple myeloma). While the deal made sense as it was in Celgene's area of expertise (blood cancer) and would allow for a path to diversify the revenue base away from their blockbuster drug Revlimid, it brings the question if the purchase price was too rich or if any of their assumptions in future revenue and/or time to market for these acquired drugs were too aggressive. Fast forward to management's third quarter 2018 earnings call when we learned the liso-cell approval date was being pushed back from 2019 to mid-2020. Management indicated they were extending the duration of the study in order to provide more differentiation at launch, provide the adequate amount of time for the FDA's minimum expectation of duration, as well as provide some competitive advantages for their drug at launch. While there was no concern from a drug efficacy stand point, it was still a disappointment as investors are eager to see some progress in the pipeline in order to diversify away from Revlimid dependence.

The Company’s unforced errors began back in February of 2018 when the Company received a Refusal to File letter (RTF) from the U.S. FDA for their much-anticipated drug Ozanimod in relapsing multiple sclerosis (RMS). This drug had an original expected approval period last first quarter, but this setback was a delay in the MS filing acceptance and anticipated approval, pushing back the approval one full year, to the first quarter of 2019. While this ended up being an issue of needing to provide more data, rather than a clinical or efficacy issue (which would have stopped the drug in its tracks) this confused us as Celgene has submitted these filings many times before…what was missed here? It seemed like sloppy work for a management team that should have been able to breeze through this process.

The Company’s recent clinical, regulatory, and operational setbacks proved to be too much as we watched the valuation of the Company's strong pipeline of drugs deteriorate to literally nothing by our estimates. The Company has five late-stage drugs all coming to market by 2020, and any future revenue generation from those drugs was erased, seemingly due to continued concerns of the Revlimid patent cliff and management execution misfires. We did not add to our holding during the year. We maintained our position, which still held an overweight position relative to the benchmark. As we’ve written over the last year, the compounded annual earnings growth of +20% through 2020 as well as free cash flow generation of $100 billion over the next decade on a stock trading at just a single-digit forward P/E multiple is still a strong growth opportunity for the portfolio.

Fast forward to today, with news released on January 3 that Celgene was being acquired by Bristol-Meyers Squibb for $74 billion. As the companies discussed the deal with news outlets, they emphasized there will be six drugs launching over the next 24 months – five of those drugs are from the Celgene pipeline. It was Celgene’s strong pipeline of promising drugs and cancer therapies coupled with a market that had pushed the stock’s price to extremely cheap valuations which resulted in Bristol-Meyers Squibb approaching the Company for acquisition at approximately $102 per share in a cash and stock deal. The deal is expected to close during the third quarter later in the year. We will have more to say on the Bristol-Myers Squibb/Celgene combination in these Letters as to whether we will continue to hold the position in Bristol-Myers Squibb.

From David Rolfe (Trades, Portfolio)'s fourth-quarter 2018 Wedgewood Partners investor letter.

Check out David Rolfe latest stock trades

David Rolfe Comments on Celgene - Jul 13, 2018

Celgene (NASDAQ:CELG) was once again a top detractor during the quarter. We chronicled the recent pipeline disappointments and earnings guidance declines in our third quarter Client Letter back in October. We recognize that the Company needs to regain investor confidence. To that end, we continue to reiterate that the Company has a very broad pipeline, with 12 phase-III studies set to read out between now and the end of 2018. Celgene has substantially more phase III assets than any other biotech company. With nearly +20% compounded annual earnings growth through 2020 and free cash flow generation of $100 billion over the next ten years, Celgene continues to offer a compelling growth opportunity.

From David Rolfe (Trades, Portfolio)'s second quarter 2018 shareholder letter.

Check out David Rolfe latest stock trades

David Rolfe Comments on Celgene - Jan 12, 2018

Celgene (NASDAQ:CELG)



Celgene was a top detractor to performance due to a couple negative news events released during the quarter. The company announced they would discontinue a phase III trial for their drug GED-0301 in Crohn's disease (CD) and an extension trial, following a recommendation of the Data Monitoring Committee. They also decided that another phase 1 trial for Crohn's disease would not be initiated. While a phase II trial with GED-0301 in ulcerative colitis is still ongoing, the Company is currently awaiting review of data to determine their next steps for this indication. In the absence of any information on whether the trial failure was due to something specific to CD or the drug itself, it is currently assumed to be a high-risk program for that indication. This study was deemed a high risk/low-probability study, especially when compared to other IBD drugs. However, its success could have been a blockbuster Inflammation & Immunology (I&I) asset for the company, making its failure a disappointing loss.



In addition to these trial failures, during the third quarter earnings release, management brought down 2020 guidance, partially due to the discontinuation of GED-0301 program in CD. While sales were only modest in their 2020 model, management did forecast multibillion dollar peak sales potential for the drug. The largest impact to 2020 guidance, however, was weak performance of their existing drug Otezla, which experienced headwinds due to slowing growth and increased competition in the psoriatic arthritis and psoriasis markets. The updated guidance takes into account GED-0301, the market dynamics impacting Otezla, as well as reassesses the opportunities and risks associated with the remaining phase III studies expected to read out by the end of 2018. We believe management took a conservative stance with their update and yet the resulting guide maintains more than +14% revenue growth and nearly +20% earnings growth on a compounded annual basis through 2020.



We realize there will be phase III failures; and with each failure comes the potential for more risk and less growth. We reiterate that the Company has a very broad pipeline, with 12 phase 1 studies set to read out between now and the end of this year, making setbacks like these more manageable in the longer term. Celgene has substantially more phase III assets than any other biotech company. Several of these pipeline assets are not incorporated in the current 2020 guidance, as they read out at a date when any sales potential will contribute at future dates. With nearly +20% compounded annual earnings growth through 2020 and free cash flow generation of $100 billion over the next ten years, Celgene continues to offer a compelling growth opportunity.

From David Rolfe (Trades, Portfolio)'s fourth quarter 2017 shareholder commentary.

Check out David Rolfe latest stock trades

Spiros Segalas Commentary on Celgene - Jul 10, 2017

Celgene (NASDAQ:CELG) rose on positive results from a trial of an experimental compound to treat relapsed/refractory multiple myeloma. We consider Celgene, with its robust revenue and earnings, and deep pipeline, one of the biotechnology sector’s most fundamentally sound companies. As of the end of the period, the Fund focused its holdings in high-conviction biotechnology and specialty pharmaceutical companies. We expect that productive research and development activity will yield effective disease treatments that improve the quality of patients’ lives, characteristics that historically have been the source of longer-term outperformance in the sector.

From Spiros Segalas (Trades, Portfolio)' Harbor Capital Appreciation Fund Managers' second quarter 2017 commentary.

Check out Spiros Segalas latest stock trades

Top Ranked Articles about Celgene Corp

Weekly Top Insider Buys Highlight for the Week of Feb. 15 The largest Insider Buys this week were for Celgene Corp. (CELG), Yum Brands Inc. (YUM), Omega Healthcare Investors Inc. (OHI), and Zimmer Biomet Holdings Inc. (ZBH)
The largest Insider Buys this week were for Celgene Corp. (NASDAQ:CELG), Yum Brands Inc. (NYSE:YUM), Omega Healthcare Investors Inc. (NYSE:OHI) and Zimmer Biomet Holdings Inc. (NYSE:ZBH). Read more...
Lifshitz & Miller LLP Announces Investigation of Celgene Corporation, SI Financial Group, Inc., Sparton Corporation, Western Gas Partners, LP, Wirecard AG, Yangtze River Port and Logistics Limited, and YRC Worldwide, Inc.
Lyfebulb and Celgene Announce Call for Innovation Challenge Applications to Address Unmet Needs in Multiple Sclerosis
Nasdaq Rises, Fueled by Strong Results on Thursday Celgene exceeds its bottom-line estimates
U.S. stock market indexes were in positive territory on Thursday, continuing the rally that followed the Federal Reserves' decision to maintain the interest rate of 2.25% to 2.5%. The Dow Jones Industrial Average fell 0.05% to 25,00, the S&P 500 index jumped 0.90% to 2,705 and the Nasdaq Composite Index rose 1.53% to 7,292. Read more...
David Rolfe Comments on Celgene Guru stock highlight
Celgene (NASDAQ:CELG) challenged us for the quarter, and quite frankly, the full year, as management failed to deliver on their promising pipeline of drugs. In review of the year, Celgene came out swinging with their $9 billion acquisition of Juno in January 2018, which brought into the Celgene portfolio of drugs JCAR017 (now liso-cell, for B-cell non-Hodgkin lymphoma) and JCARH125 (BCMA for multiple myeloma). While the deal made sense as it was in Celgene's area of expertise (blood cancer) and would allow for a path to diversify the revenue base away from their blockbuster drug Revlimid, it brings the question if the purchase price was too rich or if any of their assumptions in future revenue and/or time to market for these acquired drugs were too aggressive. Fast forward to management's third quarter 2018 earnings call when we learned the liso-cell approval date was being pushed back from 2019 to mid-2020. Management indicated they were extending the duration of the study in order to provide more differentiation at launch, provide the adequate amount of time for the FDA's minimum expectation of duration, as well as provide some Read more...
CELGENE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Celgene Corporation - CELG
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Celgene Corporation to Bristol-Myers Squibb Company is Fair to Shareholders
Celgene (CELG) Alert: Johnson Fistel Investigates Proposed Sale of Celgene Corporation; Are Celgene Shareholders Getting a Fair Deal?
Has Celgene Entered Bargain Territory? This biotech beast looks a bit too beaten down
The last few years have been a difficult ride for investors in large-cap biotech Celgene (CELG). The stock is down 37% year-on-year and is testing five-year lows. Celgene is currently trading around $68 per share and has a market capitalization of $48 billion. Read more...
Lyfebulb Partners with Celgene to Inspire Patient-Driven Innovation in the Management of Multiple Sclerosis

Ratios

vs
industry
vs
history
PE Ratio 16.40
CELG's PE Ratio is ranked higher than
54% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 28.79 vs. CELG: 16.40 )
Ranked among companies with meaningful PE Ratio only.
CELG' s PE Ratio Range Over the Past 10 Years
Min: 15.5  Med: 36.75 Max: 86.3
Current: 16.4
15.5
86.3
Forward PE Ratio 8.53
CELG's Forward PE Ratio is ranked higher than
90% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 28.41 vs. CELG: 8.53 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 16.40
CELG's PE Ratio without NRI is ranked higher than
54% of the 243 Companies
in the Global Biotechnology industry.

( Industry Median: 28.64 vs. CELG: 16.40 )
Ranked among companies with meaningful PE Ratio without NRI only.
CELG' s PE Ratio without NRI Range Over the Past 10 Years
Min: 15.5  Med: 36.75 Max: 86.3
Current: 16.4
15.5
86.3
Price-to-Owner-Earnings 16.59
CELG's Price-to-Owner-Earnings is ranked higher than
71% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 34.35 vs. CELG: 16.59 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CELG' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 11.14  Med: 33.86 Max: 569.6
Current: 16.59
11.14
569.6
PB Ratio 10.31
CELG's PB Ratio is ranked lower than
92% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. CELG: 10.31 )
Ranked among companies with meaningful PB Ratio only.
CELG' s PB Ratio Range Over the Past 10 Years
Min: 4.02  Med: 9.85 Max: 19.35
Current: 10.31
4.02
19.35
PS Ratio 4.63
CELG's PS Ratio is ranked higher than
70% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CELG: 4.63 )
Ranked among companies with meaningful PS Ratio only.
CELG' s PS Ratio Range Over the Past 10 Years
Min: 3.11  Med: 8.63 Max: 18.46
Current: 4.63
3.11
18.46
Price-to-Free-Cash-Flow 16.18
CELG's Price-to-Free-Cash-Flow is ranked higher than
66% of the 152 Companies
in the Global Biotechnology industry.

( Industry Median: 37.07 vs. CELG: 16.18 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CELG' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.87  Med: 26.35 Max: 252.23
Current: 16.18
10.87
252.23
Price-to-Operating-Cash-Flow 15.00
CELG's Price-to-Operating-Cash-Flow is ranked higher than
67% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 29.99 vs. CELG: 15.00 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CELG' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.07  Med: 24.63 Max: 143.4
Current: 15
10.07
143.4
EV-to-EBIT 14.25
CELG's EV-to-EBIT is ranked higher than
61% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. CELG: 14.25 )
Ranked among companies with meaningful EV-to-EBIT only.
CELG' s EV-to-EBIT Range Over the Past 10 Years
Min: -30.2  Med: 26.2 Max: 50.1
Current: 14.25
-30.2
50.1
EV-to-EBITDA 12.89
CELG's EV-to-EBITDA is ranked higher than
60% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. CELG: 12.89 )
Ranked among companies with meaningful EV-to-EBITDA only.
CELG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -34  Med: 21.7 Max: 40.9
Current: 12.89
-34
40.9
EV-to-Revenue 5.20
CELG's EV-to-Revenue is ranked higher than
70% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. CELG: 5.20 )
Ranked among companies with meaningful EV-to-Revenue only.
CELG' s EV-to-Revenue Range Over the Past 10 Years
Min: 4.1  Med: 8.8 Max: 18.4
Current: 5.2
4.1
18.4
PEG Ratio 1.08
CELG's PEG Ratio is ranked higher than
63% of the 115 Companies
in the Global Biotechnology industry.

( Industry Median: 2.02 vs. CELG: 1.08 )
Ranked among companies with meaningful PEG Ratio only.
CELG' s PEG Ratio Range Over the Past 10 Years
Min: 0.61  Med: 2.04 Max: 3.26
Current: 1.08
0.61
3.26
Shiller PE Ratio 40.95
CELG's Shiller PE Ratio is ranked lower than
51% of the 86 Companies
in the Global Biotechnology industry.

( Industry Median: 42.91 vs. CELG: 40.95 )
Ranked among companies with meaningful Shiller PE Ratio only.
CELG' s Shiller PE Ratio Range Over the Past 10 Years
Min: 27.57  Med: 130.52 Max: 3102
Current: 40.95
27.57
3102
Current Ratio 2.13
CELG's Current Ratio is ranked lower than
83% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. CELG: 2.13 )
Ranked among companies with meaningful Current Ratio only.
CELG' s Current Ratio Range Over the Past 10 Years
Min: 1.35  Med: 6.82 Max: 44.53
Current: 2.13
1.35
44.53
Quick Ratio 1.99
CELG's Quick Ratio is ranked lower than
79% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. CELG: 1.99 )
Ranked among companies with meaningful Quick Ratio only.
CELG' s Quick Ratio Range Over the Past 10 Years
Min: 1.13  Med: 6.66 Max: 44.15
Current: 1.99
1.13
44.15
Days Inventory 333.16
CELG's Days Inventory is ranked lower than
91% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. CELG: 333.16 )
Ranked among companies with meaningful Days Inventory only.
CELG' s Days Inventory Range Over the Past 10 Years
Min: 105.47  Med: 297.82 Max: 411.32
Current: 333.16
105.47
411.32
Days Sales Outstanding 50.64
CELG's Days Sales Outstanding is ranked higher than
61% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. CELG: 50.64 )
Ranked among companies with meaningful Days Sales Outstanding only.
CELG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.55  Med: 57.78 Max: 71.27
Current: 50.64
50.55
71.27
Days Payable 181.57
CELG's Days Payable is ranked higher than
79% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. CELG: 181.57 )
Ranked among companies with meaningful Days Payable only.
CELG' s Days Payable Range Over the Past 10 Years
Min: 61.81  Med: 172.59 Max: 241.49
Current: 181.57
61.81
241.49

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 1.70
CELG's 3-Year Average Share Buyback Ratio is ranked higher than
97% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. CELG: 1.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CELG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -25.1  Med: -5.1 Max: 4.5
Current: 1.7
-25.1
4.5

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 10.31
CELG's Price-to-Tangible-Book is ranked lower than
99.99% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. CELG: 10.31 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CELG' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.75  Med: 10.14 Max: 474.34
Current: 10.31
1.75
474.34
Price-to-Intrinsic-Value-Projected-FCF 1.28
CELG's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
78% of the 193 Companies
in the Global Biotechnology industry.

( Industry Median: 3.12 vs. CELG: 1.28 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CELG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.24  Med: 4.14 Max: 124
Current: 1.28
1.24
124
Price-to-Median-PS-Value 0.54
CELG's Price-to-Median-PS-Value is ranked higher than
74% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. CELG: 0.54 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CELG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.51  Med: 1.87 Max: 30
Current: 0.54
0.51
30
Price-to-Peter-Lynch-Fair-Value 0.92
CELG's Price-to-Peter-Lynch-Fair-Value is ranked higher than
69% of the 64 Companies
in the Global Biotechnology industry.

( Industry Median: 1.72 vs. CELG: 0.92 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
CELG' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.36  Med: 1.61 Max: 5.1
Current: 0.92
0.36
5.1
Earnings Yield (Greenblatt) % 7.02
CELG's Earnings Yield (Greenblatt) % is ranked higher than
91% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. CELG: 7.02 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CELG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -7.5  Med: 3.2 Max: 9.3
Current: 7.02
-7.5
9.3
Forward Rate of Return (Yacktman) % 24.65
CELG's Forward Rate of Return (Yacktman) % is ranked higher than
92% of the 135 Companies
in the Global Biotechnology industry.

( Industry Median: 11.41 vs. CELG: 24.65 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CELG' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.5  Med: 3 Max: 26.9
Current: 24.65
0.5
26.9

More Statistics

Revenue (TTM) (Mil) $15,281.00
EPS (TTM) $ 5.53
Beta1.88
Volatility52.25%
52-Week Range $58.59 - 97.43
Shares Outstanding (Mil)701.02

Analyst Estimate

Dec19 Dec20 Dec21
Revenue (Mil $) 17,074 19,203 21,571
EBIT (Mil $) 8,910 10,910 12,527
EBITDA (Mil $) 9,762 12,390 14,224
EPS ($) 8.90 11.04 13.03
EPS without NRI ($) 8.90 11.04 13.03
EPS Growth Rate
(Future 3Y To 5Y Estimate)
16.56%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}